Back to results
US 2017/0319487 A1Published application
Sustained release dosage forms for a jak1 inhibitor
AssigneeIncyte Corporation
InventorsKrishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
Life of this patent
Estimating the term…
Abstract
This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
Claims23
1-45. (canceled)
A sustained release dosage form comprising
- (i) {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof;
- (ii) a first hypromellose;
- and
- (iii) a second hypromellose.
1 more element
A sustained release tablet comprising
- (i) about 100 mg on a free base basis of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof;
- (ii) a first hypromellose characterized by having an apparent viscosity at a concentration of 2% in water of about 80 cP to about 120 cP;
- (iii) a second hypromellose, characterized by having an apparent viscosity at a concentration of 2% in water of about 3000 cP to about 5600 cP,
- wherein the dosage form comprises about 8% to about 20% of the first and second hypromelloses;
- (iv) about 16% to about 22% by weight of microcrystalline cellulose;
- and
- (v) about 45% to about 55% by weight of lactose monohydrate.
4 more elements
A sustained release dosage form comprising
- (i) {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof;
- and
- (ii) hypromellose characterized by having an apparent viscosity at a concentration of 2% in water of about 3000 cP to about 5600 cP.
Dependencies are inferred from the claim text.